Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion

Current Opinion in Lipidology

Volumn 24, Issue 4, 2013, Pages 339-344

  Aviram, Michael ^a   Vaya, Jacob ^b,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL HAI COLLEGE   (Israel)

^c MIGAL Galilee Technology Center Kiryat   (Israel)

Author keywords

Atherosclerosis; Carotid plaque; Lipids; Paraoxonase

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; FATTY ACID; FLAVONOID; GLABRIDIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METAL; PHOSPHOLIPID; POLYPHENOL; QUERCETIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SURFACTANT;

ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHEMICAL COMPOSITION; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; ENZYME ACTIVITY; FAT INTAKE; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RED WINE; REVIEW;

ANIMALS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; HUMANS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC;

EID: 84880624365     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835ffcfd     Document Type: Review

References (48)

1. La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996; 2:1186-1187.
2. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:1233-1238.
3. Cohen E, Aviram M, Khatib S, et al. Increased levels of human carotid lesion linoleic acid hydroperoxide in symptomatic and asymptomatic patients is inversely correlated with serum HDL and paraoxonase 1 activity. J Lipids 2012; 2012:762560.
4. Gbandjaba NY, Ghalim N, Hassar M, et al. Paraoxonase activity in healthy, diabetic, and hemodialysis patients. Clin Biochem 2012; 45:470-474.
5. Levy E, Precourt LP, Amre D, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011; 214:20-36.
6. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000; 87:45-51.
7. Macharia M, Hassan MS, Blackhurst D, et al. The growing importance of PON1 in cardiovascular health: a review. J Cardiovasc Med (Hagerstown) 2012; 13:443-453.
8. Younis NN, Soran H, Charlton-Menys V, et al. High-density lipoprotein impedes glycation of low-density lipoprotein. Diab Vasc Dis Res 2013; 10:152-160.
9. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23:461-467.
10. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281:7657-7665.
11. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101:2510-2517.
12. Efrat M, Aviram M. Macrophage paraoxonase 1 (PON1) binding sites. Biochem Biophys Res Commun 2008; 376:105-110.
13. Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med 2011; 50:102-109.
14. Berrougui H, Loued S, Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Radic Biol Med 2012; 52:1372-1381.
15. Rosenblat M, Vaya J, Shih D, Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005; 179:69-77.
16. Martinelli N, Girelli D, Olivieri O, et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med 2009; 47:432-440.
17. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring) 2010; 18:1079-1084.
18. Paragh G, Balla P, Katona E, et al. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002; 252:63-67.
19. Nguyen SD, Hung ND, Cheon-Ho P, et al. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim Biophys Acta 2009; 1790:155-160.
20. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26:892-904.
21. Rozenberg O, Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006; 351:492-498.
22. Rajkovic MG, Rumora L, Juretic D, et al. Effect of nongenetic factors on paraoxonase 1 activity in patients undergoing hemodialysis. Clin Biochem 2010; 43:1375-1380.
23. Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat Struct Mol Biol 2004; 11:412-419.
24. Aviram M. Atherosclerosis: cell biology and lipoproteins: paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol 2012; 23:169-171.
25. Efrat M, Rosenblat M, Mahmood S, et al. Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Atherosclerosis 2009; 202:461-469.
26. Gong M, Garige M, Varatharajalu R, et al. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 2009; 379:1001-1004.
27. Boesch-Saadatmandi C, Egert S, Schrader C, et al. Effect of quercetin on paraoxonase 1 activity: studies in cultured cells, mice and humans. J Physiol Pharmacol 2010; 61:99-105.
28. Fuhrman B, Volkova N, Aviram M. Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients. Nutrition 2010; 26:359-366.
29. Khateeb J, Gantman A, Kreitenberg AJ, et al. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis 2010; 208:119-125.
30. Rosenblat M, Volkova N, Aviram M. Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2. Atherosclerosis 2010; 212:86-92.
31. Rosenblat M, Volkova N, Ward J, Aviram M. Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis 2011; 219:49-56.
32. Tavori H, Rosenblat M, Vaya J, Aviram M. Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development. Clin Lipidol 2010; 5:685-697.
33. Tavori H, Aviram M, Khatib S, et al. Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Free Radic Biol Med 2011; 50:148-156.
34. Atrahimovich D, Vaya J, Tavori H, Khatib S. Glabridin protects paraoxonase 1 from linoleic acid hydroperoxide inhibition via specific interaction: a fluorescence-quenching study. J Agric Food Chem 2012; 60:3679-3685.
35. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
36. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104:503-516.
37. Marsillach J, Camps J, Beltran-Debon R, et al. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin Invest 2011; 41:308-314.
38. Hellings WE, Peeters W, Moll FL, et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010; 121:1941-1950.
39. Stegemann C, Drozdov I, Shalhoub J, et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet 2011; 4:232-242.
40. Hermus L, Schuitemaker JH, Tio RA, et al. Novel serum biomarkers in carotid artery stenosis: useful to identify the vulnerable plaque? Clin Biochem 2011; 44:1292-1298.
41. van Lammeren GW, den Hartog AG, Pasterkamp G, et al. Asymptomatic carotid artery stenosis: identification of subgroups with different underlying plaque characteristics. Eur J Vasc Endovasc Surg 2012; 43:632-636.
42. Peeters W, de Kleijn DP, Vink A, et al. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J 2011; 32:1758-1768.
43. Hermus L, Lefrandt JD, Tio RA, et al. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010; 213:21-29.
44. Holzer M, Zangger K, El-Gamal D, et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal 2012; 17:1043-1052.
45. Holzer M, Gauster M, Pfeifer T, et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 2011; 14:2337-2346.
46. Yang WI, Lee SH, Ko YG, et al. Relationship between paraoxonase-1 activity, carotid intima-media thickness and arterial stiffness in hypertensive patients. J Hum Hypertens 2010; 24:492-494.
47. Tavori H, Aviram M, Khatib S, et al. Paraoxonase 1 protects macrophages from atherogenicity of a specific triglyceride isolated from human carotid lesion. Free Radic Biol Med 2011; 51:234-242.
48. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.